Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vor Biopharma Inc VOR

Healthcare Biotechnology
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development... see more

Recent & Breaking News (NDAQ:VOR)

Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases

Business Wire March 22, 2022

Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

GlobeNewswire March 14, 2022

Vor to Participate in Three Upcoming Investor Conferences

GlobeNewswire February 28, 2022

Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 11, 2022

Vor to Participate in Two Upcoming Investor Conferences

GlobeNewswire January 4, 2022

Vor to Participate in the JMP Securities Hematology and Oncology Summit

GlobeNewswire November 29, 2021

Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference

GlobeNewswire November 19, 2021

Vor Reports Third Quarter 2021 Financial Results and Provides Company Update

GlobeNewswire November 10, 2021

Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting

GlobeNewswire November 9, 2021

Vor to Participate in Two Upcoming Investor Conferences

GlobeNewswire November 8, 2021

Vor to Present New Platform and Preclinical Data at ASH

GlobeNewswire November 4, 2021

Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT

GlobeNewswire October 19, 2021

Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management

GlobeNewswire October 12, 2021

VOR33 Granted U.S. FDA Fast Track Designation for AML

GlobeNewswire September 9, 2021

Vor to Participate in Three Upcoming Investor Conferences

GlobeNewswire September 2, 2021

Vor Reports Second Quarter 2021 Financial Results and Provides Company Update

GlobeNewswire August 9, 2021

Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

GlobeNewswire July 8, 2021

Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs

GlobeNewswire June 17, 2021

Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp

GlobeNewswire June 11, 2021

Vor to Develop Multi-Targeted CAR-Ts with Abound Bio

GlobeNewswire June 10, 2021